Impact of (activated) factor XI inhibitors (abelacimab, asundexian, and milvexian) on coagulation assays: a pioneering multicenter study for accurate result interpretation in future patients

milvexian (BMS-986177) - BMS, J&J

abelacimab (MAA868) - Anthos Therapeutics

asundexian (BAY 2433334) - Bayer

Laurie Goubeau 1; Emmanuel Curis 2; Georges Jourdi 3

May 25, 2026